Latigo Biotherapeutics Inc.
Organization details
- Legal name
- Latigo Biotherapeutics Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Thousand Oaks
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- LTGO
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0002056611
- EIN
- 83-2625838
Board of directors
- Since 2026
-
James B. Tananbaum · DirectorSince 2026
-
Kevin Raidy · DirectorSince 2026
-
Nima Farzan · Director · President and CEOSince 2026
-
Sara Bonstein · DirectorSince 2026
- Since 2026
-
Todd N. Smith · DirectorSince 2026
Chief executives
Board connections
5 of this board's directors also sit on 13 other boards. 13 are in the same sector.
-
Sagimet Biosciences Inc. Same sectorvia Beth C. Seidenberg and Timothy P. Walbert
-
Alumis Inc. Same sectorvia James B. Tananbaum
-
Atara Biotherapeutics Inc. Same sectorvia Beth C. Seidenberg
-
BioMarin Pharmaceutical Inc. Same sectorvia Timothy P. Walbert
-
Century Therapeutics Inc. Same sectorvia Timothy P. Walbert
-
Kardigan Inc. Same sectorvia Timothy P. Walbert
-
Keros Therapeutics Inc. Same sectorvia Nima Farzan
-
Kyverna Therapeutics Inc. Same sectorvia Beth C. Seidenberg
-
Mirum Pharmaceuticals Inc. Same sectorvia Timothy P. Walbert
-
Odyssey Therapeutics Inc. Same sectorvia Timothy P. Walbert
-
Progyny Inc. Same sectorvia Beth C. Seidenberg
-
Vera Therapeutics Inc. Same sectorvia Beth C. Seidenberg
-
Xilio Therapeutics Inc. Same sectorvia Sara Bonstein
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $5,040,000
- 2 purchases by 2 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 10, 2026 | Foresite Capital Fund VI LP 10% owner | Derivative conversion | +3,117,664 | — | — |
| Aug 10, 2026 | Beth C. Seidenberg Director, 10% owner | Derivative conversion | +938,979 | — | — |
| Aug 10, 2026 | James B. Tananbaum Director, 10% owner | Derivative conversion | +3,117,664 | — | — |
| Aug 10, 2026 | Westlake BioPartners GP I, LLC 10% owner | Derivative conversion | +938,979 | — | — |
| Aug 10, 2026 | 5AM Partners VI, LLC 10% owner | Derivative conversion | +4,975,543 | — | — |
| Aug 10, 2026 | Sanofi 10% owner | Derivative conversion | +494,800 | — | — |
| Aug 10, 2026 | Foresite Capital Fund VI LP 10% owner | Derivative conversion | +445,320 | — | — |
| Aug 10, 2026 | Beth C. Seidenberg Director, 10% owner | Derivative conversion | +3,547,842 | — | — |
| Aug 10, 2026 | James B. Tananbaum Director, 10% owner | Derivative conversion | +445,320 | — | — |
| Aug 10, 2026 | Westlake BioPartners GP I, LLC 10% owner | Derivative conversion | +3,547,842 | — | — |
| Aug 10, 2026 | 5AM Partners VI, LLC 10% owner | Derivative conversion | +2,350,419 | — | — |
| Aug 10, 2026 | Sanofi 10% owner | Derivative conversion | +177,978 | — | — |
| Aug 10, 2026 | Foresite Capital Fund VI LP 10% owner | Derivative conversion | +1,125,823 | — | — |
| Aug 10, 2026 | Beth C. Seidenberg Director, 10% owner | Derivative conversion | +1,027,635 | — | — |
| Aug 10, 2026 | James B. Tananbaum Director, 10% owner | Derivative conversion | +1,125,823 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Latigo Biotherapeutics Inc.
Who is the CEO of Latigo Biotherapeutics Inc.?
Nima Farzan has been Latigo Biotherapeutics Inc.'s President and CEO since August 2026.
How many directors are on Latigo Biotherapeutics Inc.'s board?
Latigo Biotherapeutics Inc.'s board has 7 directors: Beth C. Seidenberg, James B. Tananbaum, Kevin Raidy, Nima Farzan, Sara Bonstein, Timothy P. Walbert and Todd N. Smith.
Are Latigo Biotherapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Latigo Biotherapeutics Inc. insiders bought $5.0 million of shares in 2 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="latigo-biotherapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.